Cargando…
Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab
Granulomatosis with polyangiitis and microscopic polyangiitis are anti-neutrophil cytoplasmic antibody-associated vasculitides (AAVs) that are prone to cycles of remission and relapse. The introduction of cytotoxic therapy has changed the prognosis for these diseases from typically fatal to manageab...
Autores principales: | Geetha, Duvuru, Kallenberg, Cees, Stone, John H., Salama, Alan D., Appel, Gerald B., Duna, George, Brunetta, Paul, Jayne, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322237/ https://www.ncbi.nlm.nih.gov/pubmed/25185728 http://dx.doi.org/10.1007/s40620-014-0135-3 |
Ejemplares similares
-
Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis
por: Shah, Shivani, et al.
Publicado: (2015) -
Long‐Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis
por: Merkel, Peter A., et al.
Publicado: (2021) -
Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis
por: Owczarczyk, Kasia, et al.
Publicado: (2020) -
Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator
por: Kwon, Hyeok Chan, et al.
Publicado: (2020) -
Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis
por: Brogan, Paul, et al.
Publicado: (2021)